CEO statement
"Having three clinical studies in the pipeline, all with potential to address medical needs in diseases with significant market opportunities, I feel very confident about Kancera’s opportunities."
Peter Selin, CEO Kancera
Press Releases
-
2023-11-17Kancera provides operational update in connection with release of financial interim report for third quarter 2023
-
2023-11-17Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851
-
2023-10-23Kancera reports that the phase I study of KAND145 has received regulatory approval
Events
No upcoming events are currently in the calendar